Pulmonary Arterial Hypertension Treatment With Macitentan is Safe, Effective for Patients With Systemic Sclerosis
October 14, 2019
October 14, 2019
NEW ORLEANS, Louisiana, Oct. 14 -- The American College of Chest Physicians issued the following news release:
Patients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) who were treated with macitentan had similar therapeutic and safety results as patients with PAH from both idiopathic PAH (IPAH) and heritable PAH (HPAH), which is caused by a genetic mutation that runs in families, according to Vallerie McLaughlin, MD, FCCP, from the University of . . .
Patients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) who were treated with macitentan had similar therapeutic and safety results as patients with PAH from both idiopathic PAH (IPAH) and heritable PAH (HPAH), which is caused by a genetic mutation that runs in families, according to Vallerie McLaughlin, MD, FCCP, from the University of . . .